Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Moberg Pharma ABMBGPF 49 Cash-to-Debt is 123.34 as of Jun. 2026, which is 666% above its 10-year median of 16.10. GuruFocus rates MBGPF with a GF Score™ of 49/100 and a GF Value™ of $1.21 (Fairly Valued). Among 950 Drug Manufacturers companies, Moberg Pharma AB ranks better than 89.37% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Moberg Pharma AB's cash to debt ratio for the quarter that ended in Jun. 2026 was 123.34.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Moberg Pharma ABcould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Moberg Pharma AB's Cash-to-Debt or its related term are showing as below:
MBGPF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.06 Med: 16.1 Max: 123.58
Current: 123.58
During the past 13 years, Moberg Pharma AB's highest Cash to Debt Ratio was 123.58. The lowest was 0.06. And the median was 16.10.
MBGPF's Cash-to-Debt is ranked better than 89.37% of 950
companies
in the Drug Manufacturers industry
Industry Median: 0.98
vs MBGPF: 123.58
Moberg Pharma AB (OTCPK:MBGPF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Moberg Pharma AB Cash-to-Debt Related Terms
Moberg Pharma AB Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Moberg Pharma AB's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Drug Manufacturers - Specialty & Generic subindustry, Moberg Pharma AB's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Moberg Pharma AB Cash-to-Debt vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Moberg Pharma AB's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Moberg Pharma AB's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Moberg Pharma AB (MBGPF) has a Cash-to-Debt of 123.34 as of Jun. 2026. This is 666% above median its historical median of 16.10. Over the past decade, Moberg Pharma AB's Cash-to-Debt has ranged from 0.06 to 123.58. According to the industry distribution chart, Moberg Pharma AB ranks #101 out of 950 companies in the Drug Manufacturers industry, placing it in the top 10.6%.
Is Moberg Pharma AB's Cash-to-Debt too high?
Moberg Pharma AB's current Cash-to-Debt of 123.34 is 666% above median its 10-year median of 16.10. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 123.58. The Drug Manufacturers industry median Cash-to-Debt is 0.98. Moberg Pharma AB's value of 123.34 is 12485.7% above this industry median. Based on the distribution chart, Moberg Pharma AB ranks #101 out of 950 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Moberg Pharma AB has a GF Score™ of 49/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Moberg Pharma AB's Cash-to-Debt compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Moberg Pharma AB ranks #101 out of 950 companies for Cash-to-Debt. This places Moberg Pharma AB in the top 11% of its industry — outperforming the majority of peers. The industry median Cash-to-Debt is 0.98. Moberg Pharma AB's value of 123.34 is 12485.7% above this benchmark. Historically, Moberg Pharma AB's own Cash-to-Debt has ranged from 0.06 to 123.58 over the past decade. While the company's 10-year median is 16.10 vs. the industry median of 0.98, Moberg Pharma AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Drug Manufacturers company?
The median Cash-to-Debt among Drug Manufacturers companies is 0.98, based on 950 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Moberg Pharma AB's current Cash-to-Debt of 123.34 is 12485.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Cash-to-Debt is 0.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Moberg Pharma AB's current Cash-to-Debt is 123.34, which is 666% above median its own 10-year median of 16.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Moberg Pharma AB stock overvalued right now?
Based on GuruFocus' analysis, Moberg Pharma AB (MBGPF) is currently considered Fairly Valued. The stock's GF Value™ is $1.21, compared to a current price of $1.10 — trading 9.1% below its estimated fair value. The current Cash-to-Debt is 123.34, which is 666% above median its 10-year median of 16.10 and 12485.7% above the Drug Manufacturers industry median of 0.98. Moberg Pharma AB's overall GF Score™ is 49/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Moberg Pharma AB (MBGPF), the current Cash-to-Debt is 123.34 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Moberg Pharma AB (MBGPF) Overvalued in 2026?
Based on GuruFocus' analysis, Moberg Pharma AB stock appears to be undervalued.
The current stock price of $1.10 is trading 9.1% below its estimated GF Value™ of $1.21.
GuruFocus considers Moberg Pharma AB to be Fairly Valued.
Key valuation signals for MBGPF:
Cash-to-Debt: 123.34 (666% above median its 10-year median of 16.10)
GF Value™: $1.21 vs. price of $1.10 (9.1% below fair value)
Industry Position: 12485.7% above the Drug Manufacturers median (#101 of 950)
No single metric tells the full story. See the MBGPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.
49GF Score
Get the complete analysis for MBGPF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MBGPF has been successfully added to your 
